Complain about a product or service

Bird Flu Vaccine Trials 'Encouraging'

Vaccine could also protect against other flu strains

January 4, 2008

Bird Flu • Bird Flu Not the Only Animal Disease Threat • Bird Flu Vaccine Trials 'Encouraging' • FDA Frets about Flu Drugs' Side Effects • World Not Ready For Bird Flu • Researchers: Bird Flu Pandemic Inevitable • Bird Flu Scare in Virginia • FDA Issues Flu Vaccine Guidelines • FDA Approves First Bird Flu Vaccine • More Flu Bugs Show Resistance To Anti-Virals • Seasonal Flu Shot Might Offer Some Bird Flu Protection • Experts Concerned about Tamiflu Overuse • Study Finds Much Bird Flu Planning is Misplaced • U.S. Orders More Bird Flu Vaccine • Scientists Identify Genetic Changes That Could Lead to Bird Flu Pandemic • Drug Interaction Can Render Tamiflu Ineffective • New Bird Flu Variant Renews Pandemic Concerns • Researchers Find New Weapon Against Flu Virus • Researchers Test Spreadability of Bird Flu Viruses to Humans • GlaxoSmithKline Claims Bird Flu Breaththrough • Global Corporations Struggle to Plan For Pandemic • Flu Pandemic Is "Inevitable," EU Experts Warn • Bird Flu Virus May Have Mutated In Indonesian Cases • Indonesian Nurse May Have Bird Flu • Study Warns of "Chaos" and "Panic" If Bird Flu Strikes • Investigators Find No Evidence Bird Flu Virus Has Mutated • Scientists Fear Bird Flu Virus May Have Mutated • Airlines Queasy About Quarantining Bird Flu Victims • More ...

Scientists looking for a silver bullet to stop a potential "bird" flu pandemic say they may have scored a breakthrough, developing a vaccine that should protect against all strains of the influenza virus responsible for pandemic outbreaks.

Acambis, the British drug company that developed the vaccine, says it has shown encouraging results in its first human trials.

The drug, ACAM-FLU-A, is a recombinant vaccine linked to a Hepatitis B core protein. It targets M2e, a conserved region of all influenza 'A' strains.

This approach, the company says, could overcome the need for annual vaccine reformulations and, since all pandemic influenza strains are type 'A', it could also be a potential vaccine against pandemics.

The Phase 1 trial of ACAM-FLU-A evaluated the vaccine's safety and ability to generate an immune response. The randomised, double-blind, placebo-controlled trial was conducted at multiple centers in the US and involved 79 subjects.

The trial results demonstrate that ACAM-FLU-A is well tolerated and immunogenic. While immune responses were seen in all vaccinated groups, the highest immune responses occurred in the group vaccinated with ACAM-FLU-A plus QS-21, the company said.

In parallel with the Phase 1 trial, Acambis has conducted a pre-clinical study to test whether an M2e-based vaccine could protect against the Vietnam 2004 strain(1) of H5N1 avian influenza (bird flu).

The H5N1 virus was lethal in the placebo-treated group, whereas 70 percent of those in the group vaccinated with the M2e-based vaccine from the same influenza strain were protected.

"We are very excited about these new data and believe that this highly innovative vaccine could be very attractive in such a competitive field. We will explore partnering in parallel with continued development of ACAM-FLU-A," said Ian Garland, Acambis' CEO.

Influenza is a major global threat, which the WHO estimates causes between 250,000 and 500,000 deaths every year around the world. Currently, influenza vaccines are reformulated each year to address virus mutations.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Back to the top |